SG11202102995PA - Methods for reducing aggregation of bispecific antibodies - Google Patents

Methods for reducing aggregation of bispecific antibodies

Info

Publication number
SG11202102995PA
SG11202102995PA SG11202102995PA SG11202102995PA SG11202102995PA SG 11202102995P A SG11202102995P A SG 11202102995PA SG 11202102995P A SG11202102995P A SG 11202102995PA SG 11202102995P A SG11202102995P A SG 11202102995PA SG 11202102995P A SG11202102995P A SG 11202102995PA
Authority
SG
Singapore
Prior art keywords
methods
bispecific antibodies
reducing aggregation
aggregation
reducing
Prior art date
Application number
SG11202102995PA
Other languages
English (en)
Inventor
Bharadwaj Jagannathan
Joon Huh
Michael Treuheit
Daxian Shan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11202102995PA publication Critical patent/SG11202102995PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11202102995PA 2018-10-01 2019-09-27 Methods for reducing aggregation of bispecific antibodies SG11202102995PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739542P 2018-10-01 2018-10-01
PCT/US2019/053462 WO2020072306A1 (en) 2018-10-01 2019-09-27 Methods for reducing aggregation of bispecific antibodies

Publications (1)

Publication Number Publication Date
SG11202102995PA true SG11202102995PA (en) 2021-04-29

Family

ID=70055398

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102995PA SG11202102995PA (en) 2018-10-01 2019-09-27 Methods for reducing aggregation of bispecific antibodies

Country Status (14)

Country Link
EP (1) EP3860567A4 (pt)
JP (1) JP2022512569A (pt)
KR (1) KR20210070314A (pt)
CN (1) CN112789028A (pt)
AU (1) AU2019351715A1 (pt)
BR (1) BR112021006220A2 (pt)
CA (1) CA3112655A1 (pt)
CL (1) CL2021000827A1 (pt)
EA (1) EA202190955A1 (pt)
IL (1) IL281621A (pt)
MA (1) MA53831A (pt)
MX (1) MX2021003628A (pt)
SG (1) SG11202102995PA (pt)
WO (1) WO2020072306A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538669A (ja) * 2020-08-24 2023-09-08 アムジェン インコーポレイテッド Ｂｉｔｅ、二重特異性抗体、及びメチオニンを含む医薬製剤
WO2022060878A1 (en) * 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
AU2021345124A1 (en) * 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
AU2022304662A1 (en) * 2021-06-30 2023-11-23 Amgen Inc. Method of reconstituting lyophilized formulation
WO2024059675A2 (en) * 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359384B (es) * 2011-10-11 2018-09-25 Genentech Inc Conjunto mejorado de anticuerpos bisespecificos.
CN104780940B (zh) * 2012-11-06 2017-11-07 拜耳制药股份公司 用于双特异性t细胞衔接体(bites)的制剂
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
BR112016025126B1 (pt) * 2014-05-07 2024-02-15 Takeda Pharmaceutical Company Limited Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
WO2016036678A1 (en) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
SG11201805534TA (en) * 2016-01-13 2018-07-30 Genmab As Formulation for antibody and drug conjugate thereof
TWI797073B (zh) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
CN114716557A (zh) * 2016-02-03 2022-07-08 安进研发（慕尼黑）股份有限公司 Psma和cd3双特异性t细胞接合抗体构建体
CA3060856A1 (en) * 2017-05-05 2018-11-08 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
BR112020011627A2 (pt) * 2017-12-11 2020-11-17 Amgen Inc. processo de fabricação contínuo para produtos de anticorpos biespecíficos

Also Published As

Publication number Publication date
EA202190955A1 (ru) 2021-08-17
IL281621A (en) 2021-05-31
EP3860567A4 (en) 2022-07-06
MX2021003628A (es) 2021-05-27
CN112789028A (zh) 2021-05-11
JP2022512569A (ja) 2022-02-07
BR112021006220A2 (pt) 2021-07-06
CL2021000827A1 (es) 2021-10-15
CA3112655A1 (en) 2020-04-09
MA53831A (fr) 2022-01-05
KR20210070314A (ko) 2021-06-14
AU2019351715A1 (en) 2021-04-22
EP3860567A1 (en) 2021-08-11
WO2020072306A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
IL279053A (en) Bispecific anti-PVRIG/ anti-TIGIT antibodies and methods of use
IL289946A (en) Bispecific antibodies against cd3 and cd20
IL279235A (en) DLL3-CD3 bispecific antibodies
HK1258057A1 (zh) Ii型抗cd20抗體用於降低抗藥物抗體形成
HK1256365A1 (zh) 對pd1和tim3特異性的雙特異性抗體
IL281621A (en) Methods for reducing the neutralization of bispecific antibodies
ZA201702050B (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
EP3261663A4 (en) Crystals of anti-human pd-1 monoclonal antibodies
SG10201913260VA (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
GB201710838D0 (en) Bispecific antibodies
IL269645A (en) Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of using them
ZA202004908B (en) Bispecific antibody
IL269577B (en) Bispecific antibodies anti–pd–l1–anti–tim–3
IL282355A (en) Bispecific antibodies directed to exosomes
IL284026A (en) Methods for producing heterodimeric antibodies
EP3092002A4 (en) Method of purifying monoclonal antibodies
IL286757A (en) Antibodies in specific
GB201704115D0 (en) Method of selecting for antibodies
IL271346A (en) Bispecific antibodies and methods for their preparation and use
EP3710482A4 (en) COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES
IL284086A (en) Controlled Fucosylation of Antibodies
ZA202206008B (en) Bispecific anti-ccl2 antibodies
SG11202108320PA (en) Method of selecting for antibodies
GB201914819D0 (en) Method of selecting for antibodies
GB201913333D0 (en) Method of selecting for antibodies